NKGen Biotech Inc. has entered into a Conditional Investment Agreement to acquire 46.4 million shares of NKMAX Co., Ltd. at approximately $0.36 per share, with a 10% deposit secured; the deal is subject to a competitive bidding process expected to conclude by February 2025.